ライフサイエンスコーパス: myeloperoxidase

1 uced NETosis (citrullinated histone H3, DNA, myeloperoxidase).

2 serum bound dose-dependently to solid-phase myeloperoxidase.

3 cies that are generated by their heme enzyme myeloperoxidase.

4 illations, pancreatic amylase, and pulmonary myeloperoxidase.

5 oxygen metabolites by the NADPH oxidase and myeloperoxidase.

6 panel resulted in various levels of urinary myeloperoxidase.

7 is a selective and irreversible inhibitor of myeloperoxidase.

8 onships of the mammalian peroxidases LPO and myeloperoxidase.

9 and the previously undescribed cancer target myeloperoxidase.

10 cells with endogenous expression of CD20 or myeloperoxidase.

11 was the predominant protein associated with myeloperoxidase.

12 cked lactoferrin but showed normal levels of myeloperoxidase.

13 antitation of the pro-inflammatory biomarker myeloperoxidase.

14 significant for AAT (28.71; P < 0.0001) and myeloperoxidase (62.79; P < 0.0001) over a 3-mo lag and

15 We analyzed plasma levels of myeloperoxidase (a marker of neutrophil activation), sol

16 Myeloperoxidase, a heme enzyme released by polymorphonuc

17 in the initiation of leukocyte trafficking, myeloperoxidase accumulation, and acute reduction in adi

18 nfiltration is a prerequisite for myocardial myeloperoxidase accumulation.

19 Anti-PNAG treatment reduced myeloperoxidase activation and proliferation of neutroph

20 n also significantly decreased the increased myeloperoxidase activities and osteoclast and neutrophil

21 ion, neutrophil and osteoclast densities and myeloperoxidase activities were determined in gingival t

22 features, histological characteristics, and myeloperoxidase activities.

23 ), glutathione (GSH), total cholesterol, and myeloperoxidase activity (MPO) were measured.

24 litic mice significantly reduced the colonic myeloperoxidase activity and alleviated proinflammatory

25 CM4620 also decreased myeloperoxidase activity and inflammatory cytokine expre

26 Analysis of myeloperoxidase activity and Ly6G immunostaining showed

27 onylation was dependent on NADPH oxidase and myeloperoxidase activity and was inhibited by butylated

28 ity by scoring, joint function by grid test, myeloperoxidase activity by luminescence, vascular leaka

29 roscopic damage scores, bowel thickness, and myeloperoxidase activity compared with untreated animals

30 il numbers, neutrophil CD11b expression, and myeloperoxidase activity compared with wild-type litterm

31 sis factor-alpha and interleukin-1beta), and myeloperoxidase activity followed by Ly6-G positive cell

32 and higher levels of neutrophil elastase and myeloperoxidase activity in apical surface media than in

33 indicate that the ability of EGCG to inhibit myeloperoxidase activity is one of the mechanisms by whi

34 We show here that myeloperoxidase activity leads to elevated accumulation

35 Trypsin activity, cathepsin B activity and myeloperoxidase activity on the first postoperative day

36 Together these results support targeting myeloperoxidase activity to reduce genetic damage leadin

37 For both drugs, the effect of myeloperoxidase activity was greater for TOP2B than for

38 production in the tibiotarsal joint, but not myeloperoxidase activity was significantly reduced by Sz

39 ocyte chemokines (KC, MCP-1, and RANTES) and myeloperoxidase activity were also significantly elevate

40 iments, lung protein leakage, cytokines, and myeloperoxidase activity were investigated.

41 Alveolar bone resorption and myeloperoxidase activity were statistically higher in th

42 , neutrophils, lung neutrophil accumulation (myeloperoxidase activity), and proinflammatory cytokines

43 related with reduced neutrophil recruitment, myeloperoxidase activity, and air space cytokine concent

44 ransferase, hepatic neutrophil activation by myeloperoxidase activity, and cytokine secretion at spec

45 of colonic inflammation (e.g., weight loss, myeloperoxidase activity, and Ikappabalpha accumulation)

46 Tissue inflammation, evident as increased myeloperoxidase activity, and IL-1alpha, IL-1beta, and I

47 ytic capacity, high peroxide production, low myeloperoxidase activity, and low cytoplasmic granule co

48 serum amylase activity, pathological scores, myeloperoxidase activity, and the expression of inflamma

49 ry hypertension and attenuated the pulmonary myeloperoxidase activity, as well as tissue injury and s

50 ed in aggravated airway neutrophilia, tissue myeloperoxidase activity, cytokine contents, and decreas

51 ng injuries were assessed by bacterial load, myeloperoxidase activity, endothelial permeability (pulm

52 Molecular mechanisms were evaluated by myeloperoxidase activity, gene expression of RAGE, and m

53 with controls (based on loss of body weight, myeloperoxidase activity, inflammatory cytokine producti

54 inistration significantly inhibited gingival myeloperoxidase activity, interleukin (IL)-1beta, tumor

55 nflammatory cytokine concentrations in lung, myeloperoxidase activity, Ly6G immunohistochemistry, and

56 lence of S. pneumoniae, as well as host cell myeloperoxidase activity, proinflammatory cytokine secre

57 nse, with scarring characterized by stronger myeloperoxidase activity.

58 dates, leukocyte infiltration, and increased myeloperoxidase activity.

59 ol decreased diarrhea, body weight loss, and myeloperoxidase activity.

60 nfiltration of inflammatory cells, and renal myeloperoxidase activity.

61 , complete blood cell counts, histology, and myeloperoxidase activity.

62 n Willebrand factor (VWF), thrombospondin-1, myeloperoxidase, ADAMTS-13, and active VWF (aVWF) were s

63 of environmental enteropathy (calprotectin, myeloperoxidase, alpha1-antitrypsin) and the prevalence

64 ly produced, among various possibilities, by myeloperoxidase, an enzyme implicated in inflammation pr

65 This encodes myeloperoxidase, an essential component of neutrophil az

66 of neutrophil secretory proteins, including myeloperoxidase and elastase, are associated with tissue

67 Myeloperoxidase and eosinophil peroxidase are heme-conta

68 lts suggest that peroxidase enzymes, such as myeloperoxidase and eosinophil peroxidase, may play a fu

69 le of rapidly binding and internalizing both myeloperoxidase and eosinophil peroxidase.

70 tly greater cellular expression of CD11b and myeloperoxidase and higher levels of neutrophil elastase

71 rbonaceous nature of NCS broke down by human myeloperoxidase and horseradish peroxidase enzymes, reve

72 ced neutrophil degranulation with release of myeloperoxidase and hydrogen peroxide (H(2)O(2)) and inc

73 aling regulated the release of antibacterial myeloperoxidase and lactoferrin.

74 feature of mammalian peroxidases, including myeloperoxidase and lactoperoxidase (LPO) is the existen

75 ents with various forms of crescentic GN for myeloperoxidase and neutrophils, measured serum myeloper

76 It has been documented that apoA-I, myeloperoxidase and paraoxonase 1 (PON1) form a complex

77 reactive oxygen species by NADPH oxidase and myeloperoxidase and to be mediated by FcgammaRIIIb.

78 IL-6 concentrations as well as cathepsin B, myeloperoxidase and trypsin activities were determined t

79 inflammatory biomarkers C-reactive protein, myeloperoxidase, and adiponectin reduction; EAT attenuat

80 in inflammation, such as C-reactive protein, myeloperoxidase, and alarmin S100-A9.

81 NET-bound antimicrobial proteins, elastase, myeloperoxidase, and cathepsin G, in response to these s

82 We recently showed that PON1, myeloperoxidase, and HDL bind to one another in vivo for

83 y active neutrophil primary granule enzymes, myeloperoxidase, and human neutrophil elastase.

84 Neutrophil gelatinase-associated lipocalin, myeloperoxidase, and intracellular ROS levels were highe

85 ristic histone proteins, elastase, lysozyme, myeloperoxidase, and metabolic enzymes.

86 s, double-stranded DNA, neutrophil elastase, myeloperoxidase, and myeloid-related protein 8/14 were i

87 ereas other NET assays (e.g., cell-free DNA, myeloperoxidase, and myeloperoxidase-DNA complexes) coul

88 of the biomarkers alpha-1-antitrypsin (AAT), myeloperoxidase, and neopterin.

89 e surface mobilization of azurophilic (CD63, myeloperoxidase, and neutrophil elastase) and specific (

90 ents intrinsic neutrophil proteins (eg, MPO [myeloperoxidase] and various proteinases) but can gather

91 NCA-associated vasculitis and mice with anti-myeloperoxidase (anti-MPO) antibody-induced NCGN.

92 ve decreased intracellular and surface-bound myeloperoxidase, are less capable of killing phagocytose

93 throcytes identified increased expression of myeloperoxidase as the likely mechanism accounting for t

94 Most contained myeloperoxidase, as seen in NETs in other tissues, where

95 Lung sections were stained for the myeloperoxidase assay.

96 for 4 weeks lead to significant increases in myeloperoxidase, asymmetrical dimethylarginine, and card

97 results indicate that ceruloplasmin inhibits myeloperoxidase by reducing Compound I and then trapping

98 loperoxidase and neutrophils, measured serum myeloperoxidase concentration in patients with ANCA-asso

99 permeability, increased colonic IL-1beta and myeloperoxidase concentrations, and increased CD11b-posi

100 peroxides within tumor cells by transferring myeloperoxidase-containing granules into tumor cells.

101 asma amylase activity, pancreatic edema, and myeloperoxidase content in pancreas and lungs were quant

102 decreased serum MDA and renal tissue MDA and myeloperoxidase contents.

103 to quantification of migrated neutrophils by myeloperoxidase correlation, a destructive assay that pr

104 here were significant differences in cardiac myeloperoxidase, cytokines, neutrophil, and macrophage i

105 Myeloperoxidase, D-dimer, and matrix metalloproteinase 9

106 ferent murine models of myocardial ischemia, myeloperoxidase deficiency profoundly decreased vulnerab

107 Ventricles from myeloperoxidase-deficient (Mpo(-/-)) mice showed less pr

108 Myeloperoxidase-deficient animals have attenuated GN ear

109 vivo investigations linked Cx43 breakdown to myeloperoxidase-dependent activation of matrix metallopr

110 oxytoluene and Trolox, indicating a role for myeloperoxidase-dependent lipid peroxidation.

111 gh-density lipoprotein (HDL) and a target of myeloperoxidase-dependent oxidation in the artery wall.

112 h crescentic GN had extracellular glomerular myeloperoxidase deposition that correlated significantly

113 Extracellular glomerular myeloperoxidase deposition, seen in ANCA-associated vasc

114 In contrast, plasma levels of myeloperoxidase did not differ between the groups.

115 munofluorescence microscopy, immunoblotting, myeloperoxidase-DNA complex ELISA, and flow cytometry.

116 luid was analyzed for the release of NETs by myeloperoxidase-DNA complexes using an ELISA.

117 s (e.g., cell-free DNA, myeloperoxidase, and myeloperoxidase-DNA complexes) could not.

118 potent antimicrobial produced by neutrophil myeloperoxidase during inflammation.

119 We present effects of myeloperoxidase elevating single nucleotide polymorphism

120 Myeloperoxidase emerges as a crucial mediator of postisc

121 E-101 solution is a potent myeloperoxidase enzyme system with multiple oxidative me

122 To reveal the role of myeloperoxidase for the development of ventricular arrhy

123 ent of animals with APC abrogated release of myeloperoxidase from neutrophils, a marker of neutrophil

124 In conclusion, myeloperoxidase generates sufficient HOCl within neutrop

125 as incubated in vitro with nitrating nitrite/myeloperoxidase/glucose oxidase.

126 In contrast, upon treatment with myeloperoxidase, H2O2, and NaCl, the oxidized HiPco SWCN

127 3 to hypochlorous acid (HOCl), produced by a myeloperoxidase-H2O2-Cl(-) system, and determined its re

128 omyocytes, Cx43 protein content decreased on myeloperoxidase/H2O2 incubation.

129 Myeloperoxidase has a negative impact on HDL function, w

130 1 supports the hypothesis that inhibition of myeloperoxidase has an effect on microglia.

131 utrophils strongly correlated with BAL fluid myeloperoxidase, IL-8, IL-1alpha, IL-6, granulocyte colo

132 of the mouse ileum after allo-HCT by in vivo myeloperoxidase imaging and found that infiltration leve

133 Myeloperoxidase in conditioned media from neutrophils wa

134 ory biomarkers matrix metallopeptidase-9 and myeloperoxidase in plasma and sputum; ANC lower than 1.5

135 Myeloperoxidase in tears may be a sensitive and specific

136 e recipient was connected to lower levels of myeloperoxidase in the intestinal tract of mice developi

137 for a causal rather than bystander role for myeloperoxidase in the progression of cerebrovascular di

138 These findings demonstrate the role of myeloperoxidase in the regulation of ROS levels and sens

139 potently inhibit the proinflammatory enzyme myeloperoxidase in vitro in a dose-dependent manner over

140 n analysis of ischaemic stroke subtypes, the myeloperoxidase increasing genetic risk score was strong

141 orresponding to a one allele increase in the myeloperoxidase increasing genetic risk score.

142 -deficient (CD11b(-/-)) mice and intravenous myeloperoxidase infusion revealed that neutrophil infilt

143 loplasmin was a potent inhibitor of purified myeloperoxidase, inhibiting production of hypochlorous a

144 hese factors have led to the hypothesis that myeloperoxidase inhibition could protect hematopoietic c

145 Myeloperoxidase inhibition in microvesicles derived from

146 Myeloperoxidase inhibition reduced neutrophil degranulat

147 In preclinical crescentic GN, delayed myeloperoxidase inhibition suppressed kidney damage with

148 We investigated the effect of myeloperoxidase inhibition, using the myeloperoxidase in

149 his response was blocked by the irreversible myeloperoxidase inhibitor 4-amino-benzoic acid hydrazide

150 ect of myeloperoxidase inhibition, using the myeloperoxidase inhibitor AZM198, to understand its pote

151 by the recent development of novel specific myeloperoxidase inhibitors for use in inflammatory disea

152 Myeloperoxidase is a major neutrophil antimicrobial prot

153 Myeloperoxidase is a reactive oxygen generating enzyme a

154 Myeloperoxidase is expressed exclusively in granulocytes

155 uded complement component 3; angiopoietin 2; myeloperoxidase; lactoperoxidase; major histocompatibili

156 rom prior genome-wide studies of circulating myeloperoxidase levels (P < 5 x 10-6).

157 of neutrophil elastase activity, as well as myeloperoxidase levels compared to children without bact

158 surface expression on neutrophils and lower myeloperoxidase levels in blood.

159 und that RvD5 did not reduce lung neutrophil myeloperoxidase levels in PLD2(-/-) mice compared to WT

160 (3) elevated interleukin-6 (IL-6), IL-8, and myeloperoxidase levels in the airway are indicative of s

161 g that common genetic variants that increase myeloperoxidase levels increase risk of primary intracer

162 We hypothesized that genetic determinants of myeloperoxidase levels influence the development of vasc

163 A genetic risk score reflecting elevated myeloperoxidase levels was constructed from 15 common si

164 Genetic determinants of elevated circulating myeloperoxidase levels were associated with both primary

165 Myeloperoxidase levels were determined in gingival tissu

166 tion, histopathology, malondialdehyde (MDA), myeloperoxidase levels, and antioxidant enzyme expressio

167 alveolar space, decreased total protein and myeloperoxidase levels, and lower cytokine levels in the

168 Inhibition of NADPH oxidase and myeloperoxidase lowered GSA formation in the bacterial c

169 Our observations indicate that myeloperoxidase may contribute to the generation of dysf

170 E-101 solution is a first-in-class myeloperoxidase-mediated antimicrobial developed for top

171 isocyanate derived from urea dissociation or myeloperoxidase-mediated catabolism of thiocyanate to fr

172 im was to determine the relationship between myeloperoxidase-mediated oxidative damage to apolipoprot

173 f distinct surface markers (CD106, CD162 and myeloperoxidase MPO) was analyzed.

174 oderm (PLPM) expression of neutrophil marker myeloperoxidase mpo/mpx.

175 The gingival tissue was used to quantify the myeloperoxidase (MPO) activity and tumor necrosis factor

176 al bleeding index (GBI), probing depth (PD), myeloperoxidase (MPO) activity, alveolar bone loss (ABL)

177 examining their pulmonary appearance, edema, myeloperoxidase (MPO) activity, and histopathology.

178 ic resonance (MR) imaging agent specific for myeloperoxidase (MPO) activity, could detect MPO activit

179 ally mediating inflammatory response through myeloperoxidase (MPO) and biologically promoting metasta

180 peroxidasin from other peroxidases, such as myeloperoxidase (MPO) and eosinophil peroxidase (EPO).

181 Neutrophil primary granule components, myeloperoxidase (MPO) and human neutrophil elastase (HNE

182 alcium, reactive oxygen species, the enzymes myeloperoxidase (MPO) and neutrophil elastase.

183 It also decreased the levels of H2O2, myeloperoxidase (MPO) and nitric oxide (NO) in serum and

184 , advanced protein oxidation product (APOP), myeloperoxidase (MPO) and nitric oxide (NO), while deple

185 fic DNA methylation of the autoantigen genes myeloperoxidase (MPO) and proteinase 3 (PRTN3) in leukoc

186 The most common ANCA target antigens are myeloperoxidase (MPO) and proteinase 3.

187 olitis in mice by decreasing the activity of myeloperoxidase (MPO) and the expression of pro-inflamma

188 es and their derivatives would abrogate anti-myeloperoxidase (MPO) antibody-induced NCGN in a mouse m

189 Strategies to detect and characterize myeloperoxidase (MPO) are needed, given that this "split

190 Proteinase 3 (PR3) and myeloperoxidase (MPO) are two major autoantigens in pati

191 Neutrophil myeloperoxidase (MPO) can disrupt normal EC function, al

192 ive molecular imaging technologies targeting myeloperoxidase (MPO) can reveal early inflammation asso

193 Neutrophil myeloperoxidase (MPO) catalyzes the H2O2-dependent oxida

194 Autoreactivity to myeloperoxidase (MPO) causes anti-neutrophil cytoplasmic

195 Myeloperoxidase (MPO) concentration in stool, used as a

196 Oxidants derived from myeloperoxidase (MPO) contribute to inflammatory disease

197 The pathogenesis of acquired myeloperoxidase (MPO) deficiency, a rare phenomenon obse

198 ion of hydrogen peroxide and the presence of myeloperoxidase (MPO) derived from inflammatory cells, w

199 Increased myeloperoxidase (MPO) expression and activity are associ

200 n amperometric immunosensor for detection of myeloperoxidase (MPO) in human plasma is reported.

201 ANCAs directed to proteinase 3 and myeloperoxidase (MPO) in particular are associated with

202 (NE), matrix metalloproteinases (MMPs), and myeloperoxidase (MPO) in tear washes of patients with oc

203 stric lesion area and also reduced levels of myeloperoxidase (MPO) in the gastric mucosa.

204 Myeloperoxidase (MPO) is a circulating cardiovascular di

205 Myeloperoxidase (MPO) is a critical proinflammatory enzy

206 Myeloperoxidase (MPO) is a heme peroxidase that catalyze

207 Myeloperoxidase (MPO) is a well defined autoantigen in A

208 Myeloperoxidase (MPO) is released during polymorphonucle

209 Myeloperoxidase (MPO) is synthesized by neutrophil and m

210 ls and Methods Female wild-type (n = 23) and myeloperoxidase (MPO) knock-out (n = 5) mice were infect

211 knockdown reduced brain edema and decreased myeloperoxidase (MPO) levels at 24 hours, and improved n

212 ngi, including the action of enzymes such as myeloperoxidase (MPO) or NADPH oxidase, and the release

213 The heme enzyme myeloperoxidase (MPO) participates in innate immune defe

214 oxidants including hypochlorous acid, human myeloperoxidase (MPO) plays a critical role in innate im

215 Myeloperoxidase (MPO) plays essential roles in neutrophi

216 Additionally, Scl-1 interferes with myeloperoxidase (MPO) release, a prerequisite for NET pr

217 Likely, myeloperoxidase (MPO) secreted by activated macrophages

218 eleased by E. coli, is a potent inhibitor of myeloperoxidase (MPO), a bactericidal enzyme of the host

219 concept, the device has been used to detect myeloperoxidase (MPO), a cardiovascular biomarker.

220 Activation of myeloperoxidase (MPO), a heme protein primarily expresse

221 ponse to cytarabine (AraC) and overexpressed myeloperoxidase (MPO), a heme protein that converts hydr

222 Myeloperoxidase (MPO), a key enzyme released by neutroph

223 Blockade or genetic deletion of myeloperoxidase (MPO), a key neutrophil enzyme, signific

224 n that specifically binds and inhibits human myeloperoxidase (MPO), a major player in the oxidative d

225 m of the heavy chain component of the enzyme myeloperoxidase (MPO), a well-known lysosomal peroxidase

226 ivation of neutrophil markers, Calprotectin, Myeloperoxidase (MPO), and IL-8 are significantly increa

227 -8, MMP-9, tissue inhibitor of MMP (TIMP)-1, myeloperoxidase (MPO), and neutrophil elastase (NE) in p

228 leptin and resistin, the inflammatory marker myeloperoxidase (MPO), and the cytokine receptor for nuc

229 ilic granules of human neutrophils including myeloperoxidase (MPO), azurocidin, and neutrophil elasta

230 A potent oxidizing enzyme of neutrophils, myeloperoxidase (MPO), can effectively open the corked N

231 resonance (MR) imaging probe for the enzyme myeloperoxidase (MPO), might be a more sensitive contras

232 terized gut inflammation and permeability by myeloperoxidase (MPO), neopterin (NEO), and alpha-1-anti

233 and serum matrix metalloproteinase (MMP)-9, myeloperoxidase (MPO), neutrophil elastase (NE), and MMP

234 peroxidase enzymes lactoperoxidase (LPO) and myeloperoxidase (MPO), nicotinamide adenine dinucleotide

235 NP), growth differentiation factor (GDF)-15, myeloperoxidase (MPO), placental growth factor (PlGF), s

236 nzyme-linked immunosorbent assay analysis of myeloperoxidase (MPO), tumor necrosis factor (TNF)-alpha

237 Specifically, myeloperoxidase (MPO), which is abundantly expressed in

238 sitive for either proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA, were included in our study,

239 ss toxic treatment options for patients with myeloperoxidase (MPO)-ANCA-associated GN are needed.

240 Myeloperoxidase (MPO)-ANCA-associated GN is a significan

241 Observations in experimental murine myeloperoxidase (MPO)-ANCA-associated vasculitis (AAV) s

242 We measured plasma myeloperoxidase (MPO)-DNA complexes (NETs), platelet fac

243 body, is an indispensable constituent of the myeloperoxidase (MPO)-H2 O2 -halide system that produces

244 r-Kyoto (WKY) rats were immunised with human myeloperoxidase (MPO).

245 interleukin (IL)-1beta, IL-6, TNF-alpha, and myeloperoxidase (MPO).

246 enzymes (PAD4), neutrophil elastase (NE) and myeloperoxidase (MPO).

247 s are directed against proteinase 3 (PR3) or myeloperoxidase (MPO).

248 -sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO).

249 ysfunctional and are extensively oxidized by myeloperoxidase (MPO).

250 ions in MPO encoding the neutrophilic enzyme myeloperoxidase (MPO).

251 inhibitor of metalloproteinase (TIMP)-1 and myeloperoxidase (MPO).

252 l cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO).

253 roteins leukocyte proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA).

254 Fatty-acid binding proteins (FABP) and myeloperoxidases (MPO) are associated with many chronic

255 s were observed between groups of EC and NS (myeloperoxidase [MPO], matrix metalloproteinase-9) as we

256 we measured biomarkers of gut inflammation (myeloperoxidase, neopterin), permeability (alpha-1-antit

257 The release of granule proteases, such as myeloperoxidase, neutrophil elastase, and matrix metallo

258 en the 5th and 95th percentile (0.25) was by myeloperoxidase over a 2-mo lag.Of the 3 fecal biomarker

259 se (p < 0.001), proteinase-3 (p < 0.01), and myeloperoxidase (p < 0.001).

260 e and lacunar stroke, directly implicate the myeloperoxidase pathway in the pathogenesis of cerebral

261 pport of our experimental findings, baseline myeloperoxidase plasma levels were independently associa

262 ted with CD11b expression on neutrophils and myeloperoxidase plasma levels.

263 Myeloperoxidase plays a central role in initiation and p

264 Treatment with 25 nm myeloperoxidase plus 50 mum H2O2 reduced ADAMTS13 activi

265 It is composed of porcine myeloperoxidase (pMPO), glucose oxidase (GO), glucose, s

266 by the observation of a decreased number of myeloperoxidase positive neutrophils, and concomitantly

267 vps45 deficiency showed a marked paucity of myeloperoxidase-positive cells (i.e., neutrophils).

268 ge range, 4-76 years) was mainly composed of myeloperoxidase-positive immature myelomonocytic cells w

269 del of ischemia, the post-ischemic influx of myeloperoxidase-positive neutrophils and CD14(+) monocyt

270 infection-related changes in lung histology, myeloperoxidase production, and lung weight.

271 Higher MBG was associated with higher myeloperoxidase (r=0.42, P<0.0001), B-type natriuretic p

272 species (IC50 in the range 22.4-40.6muM) and myeloperoxidase release (IC50 in the range 22.2-32.2muM)

273 Myeloperoxidase released after neutrophil and monocyte a

274 AAT and myeloperoxidase seemed to interact strongly with age, wi

275 lecule) were associated with PLT, while MPO (myeloperoxidase) showed significant association with MPV

276 -2, and MCP-1), and neutrophil infiltration (myeloperoxidase staining)).

277 ciated with high plasma levels of sTIM-3 and myeloperoxidase, suggesting activated and potentially ex

278 Inhibition or depletion of myeloperoxidase suppresses neutrophil-induced tumor cell

279 against RNA, neutrophil cytoplasmic Ags, and myeloperoxidase than do TMPD-injected wild-type BALB/c m

280 tates to hydrogen peroxide, which is used by myeloperoxidase to generate other oxidants, including th

281 ed back the dramatic reduction in neutrophil myeloperoxidase to the myeloid progenitors showing down-

282 Compound I, the Fe(V) redox intermediate of myeloperoxidase, to Compound II, which has Fe(IV) in its

283 e inflammatory biomarkers (interferon-gamma, myeloperoxidase, tumor necrosis factor, interleukin 6, s

284 it induced significantly elevated levels of myeloperoxidase, tumor necrosis factor, monocyte chemoat

285 Within neutrophil phagosomes, myeloperoxidase uses superoxide generated by the NADPH o

286 No significant alterations in the levels of myeloperoxidase, VEGF, and collagen were noted.

287 Ex vivo, myeloperoxidase was demonstrated to induce fibroblast-to

288 At 28 months, myeloperoxidase was elevated in the WSH and nutrition ar

289 mic inflammation during atherogenesis, human myeloperoxidase was incubated with glycine, H2O2, malond

290 Myeloperoxidase was negatively associated with weight (W

291 Phagocyte NADPH oxidase but not myeloperoxidase was required for MGAS2221 clearance.

292 Here, by quantifying extracellular DNA or myeloperoxidase, we demonstrate that APC binds human leu

293 hods: Colonic concentrations of IL-1beta and myeloperoxidase were determined by ELISA, and colonic in

294 atment; and (3) levels of sCD25, sTIM-3, and myeloperoxidase were inversely correlated with degree of

295 (zonula occludens 1), and neutrophil influx (myeloperoxidase) were assessed using immunohistochemistr

296 Gly domain-containing linker protein 2, and myeloperoxidase) were differentially regulated in monocy

297 that related to intestinal function-AAT and myeloperoxidase-were associated with small but highly st

298 active protein, interleukin-receptor 1A, and myeloperoxidase, whereas MR-pro-ADM levels correlated wi

299 thione peroxidase, serum catalase, and colon myeloperoxidase while decreasing total fecal short-chain

300 ular inflammation, but prior studies linking myeloperoxidase with stroke risk have been inconclusive.